Literature DB >> 8296660

Cyclosporin A therapy for Wegener's granulomatosis.

N B Allen1, D S Caldwell, J R Rice, R M McCallum.   

Abstract

Five patients with active Wegener's granulomatosis were treated with the immunosuppressive agent Cyclosporin A, along with low dose prednisone. All five patients had previously taken cyclophosphamide, but further treatment with this agent was not desired, either due to patient choice, drug toxicity or malignancy. In initial doses of up to 5mg/kg/day, CyA showed efficacy but when lowered to 1-2mg/kg/day, mild disease flares occurred. CyA may provide an alternative to traditional therapy in selected patients with WG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296660     DOI: 10.1007/978-1-4757-9182-2_85

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 2.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

3.  The treatment of Wegener's granulomatosis.

Authors:  R A DeRemee
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

Review 4.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Small-vessel vasculitis: therapeutic management.

Authors:  Carol A Langford
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

6.  Lingual infarction in Wegener's Granulomatosis: a case report and review of the literature.

Authors:  Lachlan M Carter; Eitan Brizman
Journal:  Head Face Med       Date:  2008-08-21       Impact factor: 2.151

Review 7.  Wegener's granulomatosis: current and upcoming therapies.

Authors:  Carol A Langford
Journal:  Arthritis Res Ther       Date:  2003-05-29       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.